Every major biotech conference floods one city with the exact investors, partners, and KOLs you need to reach – for exactly one week a year. Most companies show up with a generic booth and a stack of one-pagers. We build the booth, the investor day, and the conference-city media plan around the specific meetings you need to have.
The Problem
Conference booths built for foot traffic, not the buyers who matter
JPM Healthcare Conference happens the same week every January in San Francisco, and the people who move your company – buy-side analysts, potential partners, KOLs – are booked in back-to-back private meetings, not walking the exhibit floor. A generic 10×10 booth with a pull-up banner competes with two hundred identical setups at JPM, ASH, ASCO, or BIO. If your presence does not give a specific person a specific reason to route to you, the spend produces booth traffic and nothing else.
Investor days are staged like sales meetings, not life sciences briefings
Most investor days rent a hotel ballroom, project a slide deck, and call it done. For a company with real pipeline depth, that format wastes the one day a year every analyst covering you is in the same room. A built environment – a mechanism-of-action walkthrough, a physical model of your platform, a room sequenced around the questions the desk actually asks – changes how much of that day converts into calibrated coverage instead of a repeat of your S-1.
DTC and disease-awareness OOH gets bought like a consumer campaign, then stalls in review
Consumer-facing pharma companies buying transit or billboard space for a disease-awareness or DTC push often plan the media buy before medical, legal, and regulatory review is scoped. Fair balance requirements and MLR turnaround determine what the creative can say and how much space it needs – they are not something you bolt on after the layout is locked. Campaigns planned out of that order either get pulled mid-flight or launch with fair balance copy so dense it defeats the format.
Airport and transit near conference cities go to whoever books first
Every flagship biotech conference floods one airport, one hotel corridor, and one transit system with your exact target audience for exactly one week. If you are not running airport OOH or hotel-corridor placements timed to JPM week or ASCO week, a better-funded competitor buys that inventory and reaches your target list before they ever set foot in your booth.
How We Help
Our assessment starts with your conference calendar, not a media plan. We map which shows matter for your stage – JPM Healthcare Conference in January if you need investor and partner reach, ASH or ASCO if abstract data and KOL relationships drive the calendar, BIO International Convention for partnering-heavy stages – and audit what your current presence actually earns: meetings booked, badge scans with real follow-up, media mentions. Most biotech companies attend four or five conferences a year with the same booth kit and no read on which ones produce anything.
Strategy development builds a presence around the specific meetings you need to have, not the square footage you can afford. For a booth, that means designing the experience around the one or two things a partner, analyst, or KOL should understand by the time they leave, and building the meeting-scheduling motion that gets the right people there on purpose. For an investor day, it means sequencing the room, the walkthrough, and the Q&A around the questions the desk will actually ask.
Execution covers design and build for booth environments and investor day staging, including any physical or interactive elements that make your platform legible to a non-scientist in ninety seconds. We coordinate with your medical affairs and regulatory teams on anything patient-facing so the experience is compliant before it is built, not after.
For DTC and disease-awareness OOH, we sequence MLR review into the media timeline from day one, so fair balance requirements shape the creative brief instead of gutting it after the buy is locked. For conference-city airport and transit buys, we time placements to the exact week your target list is in that city, so impressions land on people flying in for JPM or ASCO, not a generic regional audience.
Measurement here is not impressions. We track meetings booked and held during the conference, lead capture quality against your actual target list, media and analyst coverage generated during show week, and for DTC campaigns, message recall alongside a fair-balance compliance audit. A biotech OOH and experiential program is working when the right ten people had the right conversation, not when the booth logged the most traffic.
What we deliver
- Conference calendar and presence audit – which shows earn meetings and which are booth rental with no return
- Booth and investor day experience design – built around the specific audience and question set for that room
- MLR-sequenced DTC and disease-awareness OOH planning – creative and regulatory review scoped together, not in sequence
- Conference-week airport and transit media plan – timed to the exact city and week your target list is traveling
JPM Healthcare week is not a conference – it is the one week a year every investor, partner, and analyst who matters is standing on the same three blocks in San Francisco. Most biotech companies spend that week handing out pens.
Our Methodology
Our experiential build for biotech and pharma runs on the conference calendar, not a generic clock. Booth and investor day work for JPM Healthcare Conference has to start by September for a January show – venue-adjacent space, staging vendors, and investor meeting scheduling all lock months in advance. ASH in December, ASCO in June, and BIO follow the same rule on their own timelines: we work backward from the show date to lock design, build, and outreach with enough runway that nothing gets rushed into a generic booth kit.
Phase one is the audit and calendar mapping described above, plus a review of your regulatory and medical affairs sign-off process, so we know how much lead time creative and DTC OOH review actually need. Phase two builds the experience – booth design, investor day staging, or DTC media plan – with medical, legal, and regulatory involved from the first draft, not the final approval. Phase three executes the show week or campaign flight, staffs the meeting-scheduling motion, and tracks what actually converts into investor, partner, and physician relationships.
A booth vendor or media buyer builds what you ask for. We start from your pipeline stage and the specific meetings you need at that conference, and we know the difference between what an investor wants to see at JPM and what a KOL wants to see at ASCO – because those require two different rooms.
How We Work
Engagements built around a single flagship conference – JPM, ASH, ASCO, or BIO – typically run 8-12 weeks of active build leading into the show, with a debrief and measurement pass in the two weeks after. Companies running a full conference-circuit program, three or four shows a year plus an investor day, work with us on an ongoing retainer so the calendar, creative, and regulatory review process stay consistent show to show instead of getting rebuilt from scratch each time.
Our team includes an experiential designer who owns booth and investor day builds, a media planner who handles DTC and conference-city OOH buys, and an account lead who coordinates with your medical, legal, and regulatory reviewers so nothing stalls in approval during the final weeks before a show. From your side we need access to your pipeline data and messaging priorities, a named MLR or regulatory contact, and your target meeting list for the conference.
Cadence tightens as the show date approaches: monthly planning calls early on, weekly during the eight weeks before a flagship conference, and daily coordination during show week itself. Within two weeks after the show we run a debrief covering meetings held, coverage generated, and what changes for the next conference on the calendar.
Most companies see the clearest return in their second cycle with us, once the meeting-scheduling motion and creative templates are built and reusable. The first show is where we learn your audience and your regulatory review timeline in real conditions.
- Investor and partner meetings booked and held during flagship conference weeks
- KOL and analyst engagement quality at ASH, ASCO, and BIO
- Media and trade coverage generated during show week
- DTC and disease-awareness campaign reach in target geographies, with fair-balance compliance intact
If your biotech & pharma company needs ooh & experiential leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does OOH and experiential cost for a biotech or pharma company?
A single-conference build – booth or investor day experience for JPM, ASH, ASCO, or BIO – typically runs $40K-$120K depending on staging complexity and whether medical affairs materials need custom design. DTC and disease-awareness OOH campaigns scale with media market size and flight length, and we scope MLR review time into that number so it does not become a hidden cost later.
How far in advance do we need to start planning for a conference like JPM Healthcare?
For JPM Healthcare Conference in January, we need to start by September – venue-adjacent space, staging vendors, and investor meeting scheduling all lock months out. ASH in December and ASCO in June follow similar lead times relative to their own dates.
How does the experiential team work with our medical, legal, and regulatory reviewers?
We build MLR and regulatory review into the planning timeline from the first creative draft, with a named reviewer included on project calls rather than a document dropped in at the end. For DTC and disease-awareness OOH, fair balance requirements shape the creative brief itself, not just the final sign-off.
What makes Winston Francois different from a conference booth vendor or media buyer?
A booth vendor builds what you ask for and a media buyer books what you tell them to book. We start from your pipeline stage and the specific meetings you need at that conference, then design the booth, investor day, or media plan to earn those meetings.
How do you measure ROI on a conference booth or investor day experience?
We track meetings booked against your actual target list, meetings held versus meetings scheduled, and follow-up conversations generated in the weeks after the show. For investor days, we track analyst coverage and question quality from post-event notes.
What stage of biotech or pharma company is the right fit for this service?
Companies with a pipeline story worth explaining in person – typically Series B through commercial stage – get the most from experiential investment, since the format depends on having something specific to show. Pre-clinical companies with a single early asset often get more value from a smaller, sharper investor day than a full conference circuit.
